Cargando…

Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease

BACKGROUND: Proenkephalin (PENK) and prodynorphin (PDYN) are peptides mainly produced by the striatal medium spiny projection neurons (MSNs) under dopaminergic signaling. Therefore, they may represent candidate biomarkers in Huntington’s disease (HD) and Parkinson’s disease (PD), two neurodegenerati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barschke, Peggy, Abu-Rumeileh, Samir, Al Shweiki, M. H. D. Rami, Barba, Lorenzo, Paolini Paoletti, Federico, Oeckl, Patrick, Steinacker, Petra, Halbgebauer, Steffen, Gaetani, Lorenzo, Lewerenz, Jan, Ludolph, Albert Christian, Landwehrmeyer, Georg Bernhard, Parnetti, Lucilla, Otto, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Short Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363351/ https://www.ncbi.nlm.nih.gov/pubmed/35737109 http://dx.doi.org/10.1007/s00415-022-11187-8

Ejemplares similares

Prodynorphin and Proenkephalin in Cerebrospinal Fluid of Sporadic Creutzfeldt–Jakob Disease
por: Abu-Rumeileh, Samir, et al.
Publicado: (2022)

Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
por: Barba, Lorenzo, et al.
Publicado: (2022)

Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
por: Barba, Lorenzo, et al.
Publicado: (2022)

Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder
por: Al Shweiki, MHD Rami, et al.
Publicado: (2020)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
por: Niemela, Valter, et al.
Publicado: (2020)

High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease
por: Abu‐Rumeileh, Samir, et al.
Publicado: (2023)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

Increased expression of proenkephalin and prodynorphin mRNAs in the nucleus accumbens of compulsive methamphetamine taking rats
por: Cadet, Jean Lud, et al.
Publicado: (2016)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
por: Bellomo, Giovanni, et al.
Publicado: (2021)

Plasma β‐synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy
por: Abu‐Rumeileh, Samir, et al.
Publicado: (2023)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

CSF Ubiquitin Levels Are Higher in Alzheimer’s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease
por: Abu-Rumeileh, Samir, et al.
Publicado: (2020)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit: Blicke zurück und Blicke voraus
por: Frank, Wiebke, et al.
Publicado: (2021)

Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis
por: Menculini, Giulia, et al.
Publicado: (2021)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Assessing GFR With Proenkephalin
por: Beunders, Remi, et al.
Publicado: (2023)

Serum β-synuclein, neurofilament light chain and glial fibrillary acidic protein as prognostic biomarkers in moderate-to-severe acute ischemic stroke
por: Barba, Lorenzo, et al.
Publicado: (2023)

Behavioural characterization of prodynorphin knockout mice
por: Schunk, Eduard, et al.
Publicado: (2008)

A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
por: Gaetani, Lorenzo, et al.
Publicado: (2018)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

CSF SerpinA1 in Creutzfeldt–Jakob disease and frontotemporal lobar degeneration
por: Abu‐Rumeileh, Samir, et al.
Publicado: (2020)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection
por: Bellingacci, Laura, et al.
Publicado: (2021)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

Input–output connections of LJA5 prodynorphin neurons
por: Agostinelli, Lindsay J., et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
por: Lanari, Alessia, et al.
Publicado: (2009)

Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
por: Gómez de San José, Nerea, et al.
Publicado: (2021)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients
por: Halbgebauer, Rebecca, et al.
Publicado: (2022)

Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases
por: Halbgebauer, Steffen, et al.
Publicado: (2022)

Modified serpinA1 as risk marker for Parkinson’s disease dementia: Analysis of baseline data
por: Halbgebauer, Steffen, et al.
Publicado: (2016)

Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
por: Witzel, Simon, et al.
Publicado: (2021)

Influence of estrous cycle on explorative behaviour of wild-type and prodynorphin knockout mice
por: Rosskothen, Iris, et al.
Publicado: (2008)

Molecular signaling underlying bulleyaconitine A (BAA)-induced microglial expression of prodynorphin
por: Li, Teng-Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4172v9kgrvjf7rr3gjf5qsjsg8